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Introduction
Mesangial cell proliferation is a prominent finding of var-
ious human diseases like membranoproliferative glomer-
ulonephritis, lupus nephritis, IgA- and diabetic
nephropathy. Despite increasing knowledge on disease
mechanisms therapeutical options are very limited. The
NO-cGMP pathway has been linked with cell prolifera-
tion and matrix expansion. In our studies, we investigated
the effects of direct sGC stimulation using BAY 41–2272
and PDE 5 inhibition using vardenafil on the early phase
of experimental mesangial proliferative glomerulonephri-
tis (anti-Thy1 nephritis) in the rat.
Methods
Two separate studies were performed. First, experimental
glomerulonephritis was induced in 16 rats, 8 rats received
BAY 41–2272 (10 mg/kg bw) by daily oral gavage, 8 rats
received placebo. Additional experiments were performed
to exclude relevant effects on healthy kidneys and due to
changes of blood pressure.
In a second study, 8 rats received vardenafil (10 mg/kg
bw) twice daily by oral gavage and 8 rats served as placebo
controls. During each experiment survival biopsies were
performed on day 2, sacrificial biopsies on day 6. Blood,
urine and renal tissues were collected. For measurement
of glomerular cGMP levels additional, identical experi-
ments were performed in both studies using 10 rats (5
treatment, 5 controls). Glomeruli were isolated by
sequential sieving and samples were immediately shock
frozen and stored until analysis.
Results
Immunohistochemical staining of frozen tissue sections
localized sGC as well as PDE 5 to the mesangium.
Increased cGMP levels could be detected after sGC stimu-
lation (4005 +- 2752 fmol/l) and PDE 5 inhibition (1567
+- 417 fmol/ml) in glomerular extracts. In the presence of
equal disease induction (by equal mesangiolysis score on
day 2), sGC stimulation and PDE 5 inhibition signifi-
cantly reduced glomerular (P < 0.05) and mesangial cell
proliferation (P < 0.05) on day 6. In parallel, glomerular
matrix expansion was significantly prevented in rats
exposed to sGC stimulation and PDE 5 inhibition com-
pared to placebo controls on day 6 (P < 0.01). In contrast,
no differences could be detected regarding apoptosis
(TUNEL assay), formation of microaneurysms (JG-12),
platelet accumulation (PL-1), and ED-1 positive mono-
cytes/macrophages. Proteinuria was decreased due to sGC
stimulation but not to treatment with the PDE 5 inhibitor.
Conclusion
Our studies demonstrate that direct sGC stimulation as
well as specific inhibition of PDE 5 lead to increased
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glomerular/mesangial cGMP levels. Both substances
thereby prevent mesangial cell proliferation and matrix
expansion during experimental mesangial proliferative
glomerulonephritis. Both treatment options could there-
fore be considered as a therapeutical strategy for mesang-
ial proliferative glomerulonephritis in man.Page 2 of 2
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